CAPR Class Action Alert: Capricor Therapeutics Clinical Data Issues and Subsequent 64% Stock Drop Lead to Investor Securities Fraud Class Action to Recover Losses
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Leading securities law firm...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.